ABBVIE INC (ABBV) 145.14 +0.12 (+0.08%)
145.14 +0.12 (+0.08%)
US00287Y1091 - Common Stock - After market: 144.87 -0.27 (-0.19%)
Fundamental Rating
We assign a fundamental rating of 5 out of 10 to ABBV. ABBV was compared to 641 industry peers in the Biotechnology industry. Both the profitability and the financial health of ABBV get a neutral evaluation. Nothing too spectacular is happening here. ABBV has a correct valuation and a medium growth rate.
Profitability
Profitability Rating
ABBV's Return On Equity of 83.42% is amongst the best returns of the industry. ABBV outperforms 94% of its industry peers. The industry average return on equity is 22.42%.
The Piotroski-F score of ABBV is 8.00. This is a very strong score and indicates great health and profitability for ABBV.
ABBV's Profit Margin of 23.08% is in line with the rest of the industry. The industry average Profit Margin is 27.64%.
ABBV's Return On Assets of 9.44% is worse than the rest of the industry. The industry average Return On Assets is 12.39%.
VS Industry
ROA (9.44%) VS Industry: 32% outperformed.
0.11
52.28
ROE (83.42%) VS Industry: 94% outperformed.
0.21
217.75
Profit Margin (23.08%) VS Industry: 41% outperformed.
0.84
1,971.30
Valuation
Valuation Rating
The Price/Earnings Ratio is 10.69, which indicates a very decent valuation of ABBV.
ABBV's low PEG Ratio, which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
Compared to an average industry Price/Earning Ratio of 11.94, ABBV is valued in line with its industry peers.
With a Forward Price/Earnings Ratio of 12.22, ABBV is valued correctly.
Compared to an average industry Enterprise Value to EBITDA ratio of 11.19, ABBV is valued in line with its industry peers.
When comparing the current price to the book value of ABBV, we can conclude it is valued rather expensively. It is trading at 16.05 times its book value.
When comparing the price book ratio of ABBV to the average industry price book ratio of 1.91, ABBV is valued more expensive than its industry peers. 96% of the companies listed in the same industry are valued cheaper.
VS Industry
Price/Earnings (10.69) VS Industry: 60% outperformed.
434.00
1.04
Price/Book (16.05) VS Industry: 4% outperformed.
440.81
0.07
Enterprise Value/ EBITDA (11.19) VS Industry: 50% outperformed.
2,439.45
0.15
Growth
Growth Rating
The Earnings Per Share has grown by an nice 10.50% over the past year.
The Earnings Per Share has been growing by 21.34% on average over the past 5 years. This is a very strong growth
The Revenue has been growing by 16.99% on average over the past 5 years. This is quite good.
ABBV is expected to show a small growth in Earnings Per Share. In the coming 5 years, the EPS will grow by 1.22% yearly.
ABBV shows a small growth in Revenue. In the last year, the Revenue has grown by 4.80%.
The Revenue is expected to grow by 1.09% on average over the next 5 years.
The EPS growth is decreasing: in the next 5 years the growth will be less than in the last years.
The Revenue growth is decreasing: in the next 5 years the growth will be less than in the last years.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | 21.34% | 17.03% | 10.5% | 11.55% | -3.22% | -2.56% | 1.22% |
| Revenue | 16.99% | 19.72% | 4.8% | 3.66% | -1.88% | -1.25% | 1.09% |
Health
Health Rating
ABBV is in better financial health than average in its industry. Its Altman-Z score is much better than the industry average of -0.14.
ABBV has a very good Piotroski-F score of 8.00. This indicates a great health and profitability for ABBV.
An Altman-Z score of 2.13 indicates that ABBV is not a great score, but indicates only limited risk for bankruptcy at the moment.
ABBV has a Current Ratio of 0.93. This is a bad value and indicates that ABBV is not financially healthy enough and could expect problems in meeting its short term obligations.
When comparing the Current Ratio of ABBV to the average industry Current Ratio of 6.18, ABBV is less able to pay its short term obligations than its industry peers. 95% of its industry peers have a better Current Ratio.
A Quick Ratio of 0.83 indicates that ABBV may have some problems paying its short term obligations.
Compared to an average industry Quick Ratio of 6.05, ABBV is worse placed to pay its short term obligations than its industry peers. 95% of its industry peers have a better Quick Ratio.
Compared to an average industry Debt to Equity Ratio of 0.00, ABBV is requires more financing than its industry peers. 98% of its industry peers have a better Debt to Equity Ratio.
VS Industry
Debt/Equity (3.78) VS Industry: 2% outperformed.
15.37
0.00
Quick Ratio (0.83) VS Industry: 5% outperformed.
0.04
84.53
Current Ratio (0.93) VS Industry: 5% outperformed.
0.08
85.09
Altman-Z (2.13) VS Industry: 64% outperformed.
-2,797.49
667.93
Dividend
Dividend Rating
Compared to an average industry Dividend Yield of 3.55, ABBV pays a better dividend. On top of this ABBV pays more dividend than 100% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.42, ABBV pays a better dividend.
On average, the dividend of ABBV grows each year by 13.15%, which is quite nice.
ABBV has paid a dividend for at least 10 years, which is a reliable track record.
With a Yearly Dividend Yield of 3.85%, ABBV has a reasonable but not impressive dividend return.
ABBV's earnings are declining while the Dividend Rate has been growing. This means the dividend growth is most likely not sustainable.
73.83% of the earnings are spent on dividend by ABBV. This is not a sustainable payout ratio.
VS Industry
Dividend Yield (3.85%) VS Industry: 100% outperformed.
2.98
3.85
ABBVIE INC145.14
NYSE:ABBV (2/7/2023, 7:21:58 PM)+0.12 (+0.08%)
| GICS Sector | Health Care | ||
| GICS IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences | ||
| GICS Industry | Biotechnology | ||
| Earnings (Last) | 10-28 2022-10-28/bmo | Earnings (Next) | 02-09 2023-02-09/amc |
| Inst Owners | 68.41% | Inst Owner Change | -1.18% |
| Ins Owners | 0.1% | Ins Owner Change | 0% |
| Market Cap | 256.68B | Analysts | 75.15 |
| Price Target | 165.75 (14.2%) | ||
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.85% |
| Dividend Growth(5Y) | 13.15% | DP | 73.83% |
| Div Incr Years | 9 | Div Non Decr Years | 9 |
| Ex-Date | 01-12 2023-01-12 (1.48) | ||
| EPS beat(2) | 1 | Avg EPS beat(2) | 0.06% |
| Min EPS beat(2) | -0.31% | Max EPS beat(2) | 0.42% |
| EPS beat(4) | 2 | Avg EPS beat(4) | 0% |
| Min EPS beat(4) | -1.24% | Max EPS beat(4) | 1.11% |
| Revenue beat(2) | N/A | Avg Revenue beat(2) | -2.44% |
| Min Revenue beat(2) | -2.58% | Max Revenue beat(2) | -2.31% |
| Revenue beat(4) | N/A | Avg Revenue beat(4) | -2.47% |
| Min Revenue beat(4) | -2.58% | Max Revenue beat(4) | -2.31% |
| PT rev (1m) | 1.06% | PT rev (3m) | 2.85% |
| EPS NQ rev (1m) | -2.82% | EPS NQ rev (3m) | -3.38% |
| EPS NY rev (1m) | 0% | EPS NY rev (3m) | 0.01% |
| Revenue NQ rev (1m) | -0.12% | Revenue NQ rev (3m) | -0.98% |
| Revenue NY rev (1m) | 0% | Revenue NY rev (3m) | -0.41% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.69 | ||
| Fwd PE | 12.22 | ||
| P/S | 4.44 | ||
| P/FCF | 11.71 | ||
| P/OCF | 11.36 | ||
| P/B | 16.05 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.19 |
| EPS(TTM) | 13.58 | EY | 9.36% |
| EPS(NY) | 11.88 | Fwd EY | 8.18% |
| FCF(TTM) | 12.4 | FCFY | 8.54% |
| OCF(TTM) | 12.77 | OCFY | 8.8% |
| SpS | 32.69 | BVpS | 9.04 |
| TBVpS | -47.76 | PEG (NY) | 0.93 |
| PEG (5Y) | 0.5 | ||
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.44% | ||
| ROE | 83.42% | ||
| ROIC | 16.2% | ||
| ROICexc | 18.19% | ||
| ROICexgc | N/A | ||
| OM | 34.24% | ||
| PM | 23.08% | ||
| GM | 71.16% |
| ROICexgc(3y) | N/A | ROICexcg growth 3Y | N/A |
| ROICexcg growth 5Y | N/A | ROICexc(3y) | 20.85% |
| ROICexc growth 3Y | -15.65% | ROICexc growth 5Y | 0.08% |
| OM growth 3Y | -2.03% | OM growth 5Y | -1.54% |
| PM growth 3Y | 5.72% | PM growth 5Y | -2.45% |
| GM growth 3Y | -3.47% | GM growth 5Y | -2.2% |
| F-Score | 8 | Asset Turnover | 0.41 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.78 | ||
| Debt/FCF | 3.18 | ||
| Debt/EBITDA | 2.48 | ||
| Cap/Depr | 8.07% | ||
| Profit Quality | 164.3% | ||
| Current Ratio | 0.93 | ||
| Quick Ratio | 0.83 | ||
| Altman-Z | 2.13 |
| F-Score | 8 | WACC | 8.87% |
| ROIC/WACC | N/A | Cap/Depr(3y) | 16.31% |
| Cap/Depr(5y) | 24.07% | Profit Quality(3y) | 241.05% |
| Profit Quality(5y) | 225.55% | ||
| EPS 1Y | 10.5% | EPS 3Y | 17.03% |
| EPS 5Y | 21.34% | EPS growth Q2Q | 9.91% |
| EPS Next Y | 11.55% | EPS Next 2Y | -3.22% |
| EPS Next 3Y | -2.56% | EPS Next 5Y | 1.22% |
| Revenue growth 1Y | 4.8% | Revenue growth 3Y | 19.72% |
| Revenue growth 5Y | 16.99% | Revenue growth Q2Q | 3.28% |
| Revenue Next Year | 3.66% | Revenue Next 2Y | -1.88% |
| Revenue Next 3Y | -1.25% | Revenue Next 5Y | 1.09% |
| EBIT growth 1Y | 11.33% | EBIT growth 3Y | 17.29% |
| EBIT growth 5Y | 15.19% | EBIT Next Year | 14.68% |
| EBIT Next 3Y | -1.33% | EBIT Next 5Y | 1.26% |
| FCF growth 1Y | 43.02% | FCF growth 3Y | 19.8% |
| FCF growth 5Y | 27.36% | OCF growth 1Y | 41.11% |
| OCF growth 3Y | 19.26% | OCF growth 5Y | 26.47% |
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA